Mitochondria-derived cell-to-cell communication

Cell Reports, Journal Year: 2023, Volume and Issue: 42(7), P. 112728 - 112728

Published: July 1, 2023

In addition to their intracellular mobility, mitochondria and components can exist outside the cells from which they originate. As a result, are capable of acting on non-parental distant mediate intercellular communication in physiological conditions variety pathologies. It has recently been demonstrated that this horizontal transfer governs wide range biological processes, such as tissue homeostasis, rescue injured recipient cells, tumorigenesis. addition, due mitochondria's bacterial ancestry, be recognized damage-associated molecular patterns (DAMPs) by immune leading inflammation. Here, we provide an overview most current significant findings concerning different structures extracellular by-products functions pathological context. This account illustrates ongoing expansion our understanding role mammalian organisms.

Language: Английский

---

The Circulating Biomarkers League: Combining miRNAs with Cell-Free DNAs and Proteins

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(6), P. 3403 - 3403

Published: March 17, 2024

The potential of liquid biopsy for the prognosis and diagnosis diseases is unquestionable. Within evolving landscape disease diagnostics personalized medicine, circulating microRNAs (c-miRNAs) stand out among biomarkers found in blood circulation other biological fluids due to their stability, specificity, non-invasive detection biofluids. However, complexity human limitations inherent single-marker highlight need a more integrative approach. It has been recently suggested that multi-analyte approach offers advantages over single-analyte diseases. In this review, we explore combining three well-studied classes biofluids—miRNAs, DNAs, proteins—to enhance accuracy efficacy monitoring. Initially, provide an overview each biomarker class discuss main disadvantages highlighting superiority c-miRNAs biomarkers. Additionally, challenges future directions integrating these into clinical practice, emphasizing standardized protocols further validation studies. This integrated revolutionize precision medicine by offering insights mechanisms, facilitating early detection, guiding therapeutic strategies. collaborative power with represents promising frontier comprehensive understanding management complex Nevertheless, several must be addressed before can translated practice.

Language: Английский

---

Neutrophils and the Systemic Inflammatory Response Syndrome (SIRS)

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(17), P. 13469 - 13469

Published: Aug. 30, 2023

We are not entirely able to understand, assess, and modulate the functioning of immune system in clinical situations that lead a systemic inflammatory response. In search for diagnostic treatment strategies (which still far from perfect), it became very important study pathogenesis participation endogenous inflammation mediators. This attempts more precisely establish role neutrophils individual phenomena occurring during an anti-inflammatory reaction, taking into account their cidal, immunoregulatory, reparative abilities. Pro- anticoagulatory properties endothelium response syndrome (SIRS) emphasised, along with resulting implications (the application immunotherapy using mesenchymal stem/stromal cells (MSCs) or IL-6 antagonists sepsis COVID-19 treatment, among others). Special attention is paid reactive oxygen species (ROS), produced by activated “respiratory burst” course SIRS; protective pathogenic these mediators highlighted. Moreover, clinically useful biomarkers SIRS (neutrophil extracellular traps, cell-free DNA, DAMP, TREMs, NGAL, miRNA, selected cytokines, ROS, recognised markers endothelial damage group adhesins means immunohistochemical techniques) related presented, diagnosing forecasting sepsis, burn disease, emphasised. Finally, examples immunomodulation antioxidative thermal injury therapy presented.

Language: Английский

---

Circulating Microbial Cell-Free DNA in Health and Disease

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(3), P. 3051 - 3051

Published: Feb. 3, 2023

Human blood contains low biomass of circulating microbial cell-free DNA (cfmDNA) that predominantly originates from bacteria. Numerous studies have detected cfmDNA in patients with infectious and non-infectious diseases, healthy individuals. Remarkable differences were found the composition subjects compared to cohorts various diseases or even diversified prognoses, implying these alterations may be associated disease development. Although function needs elucidated (whether it acts as a bystander dysbiosis key player development), several demonstrated its potential non-invasive biomarker improve diagnosis treatment efficacy. The origin is still subject much deliberation, but identified members microbiome niches, including gut, oral cavity, airways, skin. Further investigating are needed. Moreover, low-biomass prone contamination, therefore stringent negative experimental control reactions decontamination frameworks advised order detect genuine cfmDNA.

Language: Английский

---

Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay

International Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 29(5), P. 495 - 511

Published: March 29, 2024

Circulating tumor DNA (ctDNA) is the fraction of cell-free in patient blood that originates from a tumor. Advances sequencing technologies and our understanding molecular biology tumors have increased interest exploiting ctDNA to facilitate detection residual disease (MRD). Analysis as promising MRD biomarker solid malignancies has central role precision medicine initiatives exemplified by CIRCULATE-Japan project involving patients with resectable colorectal cancer. Notably, underscores prognostic significance status at 4 weeks post-surgery its correlation adjuvant therapy efficacy interim analysis. This substantiates hypothesis critical indicator relapse Despite remarkable advancements, challenges endure, primarily attributable exceedingly low concentration peripheral blood, particularly scenarios shedding intrinsic error rates current technologies. These complications necessitate more sensitive sophisticated assays verify clinical utility across all tumors. Whole genome (WGS)-based tumor-informed recently demonstrated ability detect parts-per-million range. review delineates landscape assays, highlighting WGS-based approaches forefront technique Additionally, it introduces upcoming endeavor, pan-cancer via ctDNA, forthcoming project, SCRUM-Japan MONSTAR-SCREEN-3.

Language: Английский

---

Cell-free DNA release following psychosocial and physical stress in women and men

Translational Psychiatry, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 25, 2025

Language: Английский

---

The Potential of cfDNA as Biomarker: Opportunities and Challenges for Neurodegenerative Diseases

Journal of Molecular Neuroscience, Journal Year: 2025, Volume and Issue: 75(1)

Published: March 13, 2025

Abstract Neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s (PD), multiple sclerosis (MS), and amyotrophic lateral (ALS), are characterized by the progressive gradual degeneration of neurons. The prevalence rates these disorders rise significantly with age. As life spans continue to increase in many countries, number cases is expected grow foreseeable future. Early precise diagnosis, along appropriate surveillance, continues pose a challenge. high heterogeneity neurodegenerative diseases calls for more accurate definitive biomarkers improve clinical therapy. Cell-free DNA (cfDNA), fragmented released into bodily fluids via apoptosis, necrosis, or active secretion, has emerged as promising non-invasive diagnostic tool various diseases. cfDNA can serve an indicator ongoing cellular damage mortality, neuronal loss, may provide valuable insights processes, progression, therapeutic responses. This review will first cover key aspects then examine recent advances its potential use biomarker disorders.

Language: Английский

---

Pre-Analytical Evaluation of Streck Cell-Free DNA Blood Collection Tubes for Liquid Profiling in Oncology

Diagnostics, Journal Year: 2023, Volume and Issue: 13(7), P. 1288 - 1288

Published: March 29, 2023

Excellent pre-analytical stability is an essential precondition for reliable molecular profiling of circulating tumor DNA (ctDNA) in oncological diagnostics. Therefore, vitro degradation ctDNA and the additional release contaminating genomic from lysed blood cells must be prevented. Streck Cell-Free collection tubes (cfDNA BCTs) have proposed advantages over standard K2EDTA tubes, but mainly been tested healthy individuals. Blood was collected cancer patients (n = 53) suffering colorectal 21), pancreatic 11), non-small-cell lung 21) using cfDNA BCT that were processed immediately or after 3 days (BCTs) 6 hours (K2EDTA) at room temperature. The isolated these samples characterized terms yield LINE-1 qPCR; level gDNA contamination; mutation status KRAS, NRAS, EGFR genes BEAMing ddPCR. CfDNA levels comparable both tube types not affected by prolonged storage least BCTs tubes. In addition, biospecimens stored up to demonstrated highly mutational load across all respective patient cohorts a wide range concentrations. Our data support applicability clinical oncology specimens analyses.

Language: Английский

---

The Role of Biomarkers in Diagnosis of Sepsis and Acute Kidney Injury

Biomedicines, Journal Year: 2024, Volume and Issue: 12(5), P. 931 - 931

Published: April 23, 2024

Sepsis and acute kidney injury (AKI) are two major public health concerns that contribute significantly to illness death worldwide. Early diagnosis prompt treatment essential for achieving the best possible outcomes. To date, there no specific clinical, imaging, or biochemical indicators available diagnose sepsis, of AKI based on KDIGO criterion has limitations. improve diagnostic process sepsis AKI, it is continually evolve our understanding these conditions. Delays in appropriate can have serious consequences. often occur together, patients with dysfunction more prone developing sepsis. Therefore, identifying potential biomarkers both conditions crucial. In this review, we talk about main namely neutrophil gelatinase-associated lipocalin (NGAL), proenkephalin (PENK), cell-free DNA.

Language: Английский

---

Cell-free DNA as a potential biomarker for acute myocardial infarction: A systematic review and meta-analysis

IJC Heart & Vasculature, Journal Year: 2023, Volume and Issue: 47, P. 101246 - 101246

Published: July 29, 2023

Tissue necrosis releases cell-free deoxyribonucleic acid (cfDNA), leading to rapid increases in plasma concentration with clearance independent of kidney function. To explore the diagnostic role cfDNA acute myocardial infarction (AMI). This systematic review and meta-analysis included studies patients AMI a comparator group without AMI. The quality assessment accuracy studies-2 (QUADAS-2) tool was used, determined from criteria original study. Standardised mean differences (SMD) were obtained using random-effects inverse variance model. Heterogeneity reported as I2. Pooled sensitivity specificity computed bivariate area under curve (AUC) estimated hierarchical summary receiver operating characteristics curve. Seventeen identified involving 1804 (n = 819 group, n 985 group). Circulating concentrations greater (SMD 3.47 (95%CI: 2.54–4.41, p < 0.001)). variable methodological substantial heterogeneity (I2 98%, 0.001), possibly due quantification methodologies (Chi2 25.16, 0.001, I2 92%). Diagnostic six 804), which yielded 87% 72%-95%) 96% 92%-98%). AUC 0.96 0.93–0.98). Two relationship between peak troponin. No data for pre-existing impairment. Plasma appears be reliable biomarker injury. Inferences existing results are limited owing methodology heterogeneity.

Language: Английский

---